Jump to content

Tegafur/uracil: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
consistent citation formatting
Line 1: Line 1:
{{Short description|Chemotherapy drug used in the treatment of cancer}}
{{Short description|Chemotherapy drug used in the treatment of cancer}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
Line 39: Line 40:
| UNII = HMI5GR78FR
| UNII = HMI5GR78FR
}}
}}
'''Tegafur/uracil''' (abbreviation: UFT<ref name=":0">{{Cite web |date=2011-02-02 |title=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil |url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil |access-date=2024-06-20 |website=www.cancer.gov |language=en}}</ref>) is a [[chemotherapy]] drug combination used in the treatment of cancer, primarily [[bowel cancer]].
'''Tegafur/uracil''' (abbreviation: UFT<ref name="NCI_dictionaries_2011">{{Cite web |date=2011-02-02 |title=Tegafur-uracil |url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil |access-date=2024-06-20 | work = NCI dictionaries | publisher = National Cancer Institute, U.S. Department of Health and Human Services |language=en}}</ref>) is a [[chemotherapy]] drug combination used in the treatment of cancer, primarily [[bowel cancer]].


UFT is an oral formulation combining [[uracil]] (a [[competitive inhibitor]] of [[dihydropyrimidine dehydrogenase]]), and [[tegafur]] (a bioavailable [[5-fluorouracil]] (5-FU) [[prodrug]]) in a 4:1 molar ratio.<ref name=":0" />
UFT is an oral formulation combining [[uracil]] (a [[competitive inhibitor]] of [[dihydropyrimidine dehydrogenase]]), and [[tegafur]] (a bioavailable [[5-fluorouracil]] (5-FU) [[prodrug]]) in a 4:1 molar ratio.<ref name="NCI_dictionaries_2011" />


5-FU exhibits poor intestinal penetration<ref>{{Cite journal |last=Ahmad |first=Niyaz |last2=Albassam |first2=Ahmed A. |last3=Faiyaz Khan |first3=Mohd |last4=Ullah |first4=Zabih |last5=Mohammed Buheazah |first5=Taysser |last6=Salman AlHomoud |first6=Hussain |last7=Ali Al-Nasif |first7=Hassan |date=2022-05 |title=A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer |url=https://linkinghub.elsevier.com/retrieve/pii/S1319562X22000936 |journal=Saudi Journal of Biological Sciences |language=en |volume=29 |issue=5 |pages=3704–3716 |doi=10.1016/j.sjbs.2022.02.017 |pmc=PMC9280251 |pmid=35844373}}</ref><ref>{{Cite journal |last=Kumar |first=Anoop |last2=Singh Arya |first2=Piyush Kumar |last3=Jindal |first3=Amulya |date=2024-03-05 |title=Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment |url=https://www.tandfonline.com/doi/full/10.1080/01932691.2024.2325398 |journal=Journal of Dispersion Science and Technology |language=en |pages=1–13 |doi=10.1080/01932691.2024.2325398 |issn=0193-2691}}</ref> and significant intestinal<ref>{{Cite journal |last=Gu |first=J. |last2=Yuasa |first2=H. |last3=Hayashi |first3=Y. |last4=Watanabe |first4=J. |date=1998-08 |title=First-pass metabolism of 5-fluorouracil in the perfused rat small intestine |url=https://pubmed.ncbi.nlm.nih.gov/9743260/ |journal=Biological & Pharmaceutical Bulletin |volume=21 |issue=8 |pages=871–873 |doi=10.1248/bpb.21.871 |issn=0918-6158 |pmid=9743260}}</ref><ref name=":1">{{Cite journal |last=Yuasa |first=Hiroaki |last2=Gu |first2=Jian |last3=Hayashi |first3=Yayoi |last4=Watanabe |first4=Jun |date=2011-04-12 |title=First-pass Metabolism of 5-Fluorouracil in Rats |url=https://academic.oup.com/jpp/article/50/9/1019/6153078 |journal=Journal of Pharmacy and Pharmacology |language=en |volume=50 |issue=9 |pages=1019–1025 |doi=10.1111/j.2042-7158.1998.tb06917.x |issn=2042-7158}}</ref> and hepatic [[First pass effect|first-pass metabolism]]<ref name=":1" /> by DPD, resulting in low and erratic systemic bioavailibility as well as formation of toxic metabolites.<ref>{{Cite journal |last=Eisenmann |first=Eric D. |last2=Talebi |first2=Zahra |last3=Sparreboom |first3=Alex |last4=Baker |first4=Sharyn D. |date=2022-01 |title=Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions |url=https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13623 |journal=Basic & Clinical Pharmacology & Toxicology |language=en |volume=130 |issue=S1 |pages=23–35 |doi=10.1111/bcpt.13623 |issn=1742-7835 |pmc=PMC8665934 |pmid=34117715}}</ref> Tegafur, after being absorbed from the gastrointestinal tract and delivered to the liver by the [[Hepatic portal system|portal venous system]], is converted to the bioactive compound 5-FU by hepatic [[Cytochrome P450|cytochrome P450 enzymes]]. The surfeit of uracil meanwhile competitively inhibits hepatic DPD, preventing immediate inactivation of the just formed 5-FU.<ref name=":0" />
5-FU exhibits poor intestinal penetration<ref>{{cite journal | vauthors = Ahmad N, Albassam AA, Faiyaz Khan M, Ullah Z, Mohammed Buheazah T, Salman AlHomoud H, Ali Al-Nasif H | title = A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer | journal = Saudi Journal of Biological Sciences | volume = 29 | issue = 5 | pages = 3704–3716 | date = May 2022 | pmid = 35844373 | pmc = 9280251 | doi = 10.1016/j.sjbs.2022.02.017 }}</ref><ref>{{Cite journal | vauthors = Kumar A, Singh Arya PK, Jindal A |date=2024-03-05 |title=Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment |url=https://www.tandfonline.com/doi/full/10.1080/01932691.2024.2325398 |journal=Journal of Dispersion Science and Technology |language=en |pages=1–13 |doi=10.1080/01932691.2024.2325398 |issn=0193-2691}}</ref> and significant intestinal<ref>{{cite journal | vauthors = Gu J, Yuasa H, Hayashi Y, Watanabe J | title = First-pass metabolism of 5-fluorouracil in the perfused rat small intestine | journal = Biological & Pharmaceutical Bulletin | volume = 21 | issue = 8 | pages = 871–873 | date = August 1998 | pmid = 9743260 | doi = 10.1248/bpb.21.871 }}</ref><ref name="Yuasa_1998">{{cite journal | vauthors = Yuasa H, Gu J, Hayashi Y, Watanabe J | title = First-pass metabolism of 5-fluorouracil in rats | journal = The Journal of Pharmacy and Pharmacology | volume = 50 | issue = 9 | pages = 1019–1025 | date = September 1998 | pmid = 9811163 | doi = 10.1111/j.2042-7158.1998.tb06917.x }}</ref> and hepatic [[First pass effect|first-pass metabolism]]<ref name="Yuasa_1998" /> by DPD, resulting in low and erratic systemic bioavailibility as well as formation of toxic metabolites.<ref>{{cite journal | vauthors = Eisenmann ED, Talebi Z, Sparreboom A, Baker SD | title = Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions | journal = Basic & Clinical Pharmacology & Toxicology | volume = 130 Suppl 1 | issue = Suppl 1 | pages = 23–35 | date = January 2022 | pmid = 34117715 | pmc = 8665934 | doi = 10.1111/bcpt.13623 }}</ref> Tegafur, after being absorbed from the gastrointestinal tract and delivered to the liver by the [[Hepatic portal system|portal venous system]], is converted to the bioactive compound 5-FU by hepatic [[Cytochrome P450|cytochrome P450 enzymes]]. The surfeit of uracil meanwhile competitively inhibits hepatic DPD, preventing immediate inactivation of the just formed 5-FU.<ref name="NCI_dictionaries_2011" />


== Pharmacology ==
== Pharmacology ==
Uracil has also been stated to help protect the gastrointestinal tract from 5-FU toxicity and the related metabolites, with less side effects than 5-FU and other 5-FU related (pro)drugs.{{Citation needed|date=June 2024}}
Uracil has also been stated to help protect the gastrointestinal tract from 5-FU toxicity and the related metabolites, with less side effects than 5-FU and other 5-FU related (pro)drugs.{{Citation needed|date=June 2024}}


[[Tetrahydrofuran]] metabolites of tegafur have been shown to exhibit [[antiangiogenic]]<ref>{{Cite journal |last=Watanabe |first=Toru |date=2013 |title=Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer |url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824200/ |journal=Breast Cancer (Tokyo, Japan) |volume=20 |issue=4 |pages=302–309 |doi=10.1007/s12282-013-0451-9 |issn=1340-6868 |pmc=3824200 |pmid=23456736}}</ref> effects and improve cytocidal performance of 5-FU, particularly in patients with over-expressed [[HIF-1]].{{Citation needed|date=June 2024}}
[[Tetrahydrofuran]] metabolites of tegafur have been shown to exhibit [[antiangiogenic]]<ref>{{cite journal | vauthors = Watanabe T | title = Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer | journal = Breast Cancer | volume = 20 | issue = 4 | pages = 302–309 | date = October 2013 | pmid = 23456736 | pmc = 3824200 | doi = 10.1007/s12282-013-0451-9 }}</ref> effects and improve cytocidal performance of 5-FU, particularly in patients with over-expressed [[HIF-1]].{{Citation needed|date=June 2024}}


== Trial results ==
== Trial results ==
Trials using UFT for cancer treatment include [[pancreatic cancer]], [[colorectal cancer]],<ref name="Akasu06"/><ref>{{cite journal |vauthors=Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA |title=UFT (tegafur-uracil) in rectal cancer |journal=Ann. Oncol. |volume=19 |issue=8 |pages=1371–8 |date=August 2008 |pmid=18381370 |doi=10.1093/annonc/mdn067 |url=http://annonc.oxfordjournals.org/content/19/8/1371.full|doi-access=free }}</ref> [[liver cancer]],<ref>{{cite journal |author=Ishikawa T |title=Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma |journal=World J Gastroenterol |volume=14 |issue=18 |pages=2797–2801 |date=May 2008 |doi=10.3748/wjg.14.2797 |pmid=18473401 |pmc=2710718 |doi-access=free }}</ref> [[adenocarcinoma]] of the lung<ref>{{cite journal |vauthors=Kato H, Ichinose Y, Ohta M, etal |title=A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung |journal=N. Engl. J. Med. |volume=350 |issue=17 |pages=1713–21 |date=April 2004 |pmid=15102997 |doi=10.1056/NEJMoa032792 |doi-access=free }}</ref> and breast cancer<ref>{{cite journal |vauthors=Watanabe T, Sano M, Takashima S, etal |title=Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial |journal=J. Clin. Oncol. |volume=27 |issue=9 |pages=1368–74 |date=March 2009 |pmid=19204202 |doi=10.1200/JCO.2008.18.3939 }}</ref><ref>{{cite journal |vauthors=Nakayama T, Noguchi S |title=Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan |journal=Oncologist |volume=15 |issue=1 |pages=26–36 |year=2010 |pmid=20080863 |doi=10.1634/theoncologist.2009-0255 |pmc=3227888}}</ref> with significant gains over existing treatments, with reduced side effects, improved quality of life, improved disease free survival and/or overall survival.
Trials using UFT for cancer treatment include [[pancreatic cancer]], [[colorectal cancer]],<ref name="Akasu06"/><ref>{{cite journal | vauthors = Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA | title = UFT (tegafur-uracil) in rectal cancer | journal = Annals of Oncology | volume = 19 | issue = 8 | pages = 1371–1378 | date = August 2008 | pmid = 18381370 | doi = 10.1093/annonc/mdn067 | doi-access = free }}</ref> [[liver cancer]],<ref>{{cite journal | vauthors = Ishikawa T | title = Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma | journal = World Journal of Gastroenterology | volume = 14 | issue = 18 | pages = 2797–2801 | date = May 2008 | pmid = 18473401 | pmc = 2710718 | doi = 10.3748/wjg.14.2797 | doi-access = free }}</ref> [[adenocarcinoma]] of the lung<ref>{{cite journal | vauthors = Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M | title = A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung | journal = The New England Journal of Medicine | volume = 350 | issue = 17 | pages = 1713–1721 | date = April 2004 | pmid = 15102997 | doi = 10.1056/NEJMoa032792 | doi-access = free }}</ref> and breast cancer<ref>{{cite journal | vauthors = Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y | title = Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial | journal = Journal of Clinical Oncology | volume = 27 | issue = 9 | pages = 1368–1374 | date = March 2009 | pmid = 19204202 | doi = 10.1200/JCO.2008.18.3939 }}</ref><ref>{{cite journal | vauthors = Nakayama T, Noguchi S | title = Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan | journal = The Oncologist | volume = 15 | issue = 1 | pages = 26–36 | year = 2010 | pmid = 20080863 | pmc = 3227888 | doi = 10.1634/theoncologist.2009-0255 }}</ref> with significant gains over existing treatments, with reduced side effects, improved quality of life, improved disease free survival and/or overall survival.


==History==
==History==
The UFT combination was developed in Japan during the 1980s. UFT is approved in over 50 countries as a cancer therapy, most commonly for advanced colorectal cancer to replace 5FU, and has a low cost.<ref name=Akasu06>{{cite journal |vauthors=Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S |title=Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial |journal=Jpn. J. Clin. Oncol. |volume=36 |issue=4 |pages=237–44 |date=April 2006 |pmid=16675478 |doi=10.1093/jjco/hyl014 |url=http://jjco.oxfordjournals.org/cgi/content/full/36/4/237|doi-access=free }}</ref> "[P]atients appeared strongly to prefer treatment with [oral] UFT/LV over [intravenous] 5-FU/LV."<ref>{{cite web |url=http://www.hta.ac.uk/execsumm/summ732.shtml |title=Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation |website=www.hta.ac.uk |access-date=15 January 2022 |archive-url=https://web.archive.org/web/20091118110244/http://www.hta.ac.uk/execsumm/summ732.shtml |archive-date=18 November 2009 |url-status=dead}}</ref> In Japan, UFT is approved for cancer treatments including tumors of the colon/rectum, lung, breast, stomach, head and neck, liver, gallbladder, bile duct, pancreas, bladder, prostate, and cervix.<ref>{{Cite web|url=https://www.drugs.com/clinical_trials/merck-asco-2007-new-data-demonstrate-value-uft-important-option-patients-metastatic-colorectal-1141.html|title=Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer - Drugs.com MedNews|website=Drugs.com}}</ref> In the UK, tegafur/uracil with [[folinic acid]] is approved as first line treatment by the [[National Institute for Health and Clinical Excellence]] (NICE) for metastatic colorectal cancer.<ref>Capecitabine and tegafur uracil for [[metastatic]] colorectal cancer, [http://guidance.nice.org.uk/TA61 Technical appraisal 61]</ref>
The UFT combination was developed in Japan during the 1980s. UFT is approved in over 50 countries as a cancer therapy, most commonly for advanced colorectal cancer to replace 5FU, and has a low cost.<ref name=Akasu06>{{cite journal | vauthors = Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S | title = Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial | journal = Japanese Journal of Clinical Oncology | volume = 36 | issue = 4 | pages = 237–244 | date = April 2006 | pmid = 16675478 | doi = 10.1093/jjco/hyl014 | doi-access = free }}</ref> "[P]atients appeared strongly to prefer treatment with [oral] UFT/LV over [intravenous] 5-FU/LV."<ref>{{cite web |url=http://www.hta.ac.uk/execsumm/summ732.shtml |title=Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation |website=www.hta.ac.uk |access-date=15 January 2022 |archive-url=https://web.archive.org/web/20091118110244/http://www.hta.ac.uk/execsumm/summ732.shtml |archive-date=18 November 2009 |url-status=dead}}</ref> In Japan, UFT is approved for cancer treatments including tumors of the colon/rectum, lung, breast, stomach, head and neck, liver, gallbladder, bile duct, pancreas, bladder, prostate, and cervix.<ref>{{Cite web|url=https://www.drugs.com/clinical_trials/merck-asco-2007-new-data-demonstrate-value-uft-important-option-patients-metastatic-colorectal-1141.html|title=Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer - Drugs.com MedNews|website=Drugs.com}}</ref> In the UK, tegafur/uracil with [[folinic acid]] is approved as first line treatment by the [[National Institute for Health and Clinical Excellence]] (NICE) for metastatic colorectal cancer.<ref>Capecitabine and tegafur uracil for [[metastatic]] colorectal cancer, [http://guidance.nice.org.uk/TA61 Technical appraisal 61]</ref>


== Manufacturing and marketing ==
== Manufacturing and marketing ==
Line 64: Line 65:
{{reflist}}
{{reflist}}


== External links==
== Further reading ==
{{refbegin}}
{{refbegin|30em}}
*{{cite journal |vauthors=Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N |title=A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America |journal=Oncology (Williston Park, N.Y.) |volume=11 |issue=9 Suppl 10 |pages=128–35 |date=September 1997 |pmid=9348585 }}
* {{cite journal | vauthors = Murad A, de Andrade CA, Delfino C, Arikian S, Doyle J, Sinha N | title = A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America | journal = Oncology | volume = 11 | issue = 9 Suppl 10 | pages = 128–135 | date = September 1997 | pmid = 9348585 }}
*{{cite journal |vauthors=Yoshitani S, Takashima S |title=Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer |journal=Cancer Biother. Radiopharm. |volume=24 |issue=1 |pages=35–40 |date=February 2009 |pmid=19243246 |doi=10.1089/cbr.2008.0547 }}
* {{cite journal | vauthors = Yoshitani S, Takashima S | title = Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer | journal = Cancer Biotherapy & Radiopharmaceuticals | volume = 24 | issue = 1 | pages = 35–40 | date = February 2009 | pmid = 19243246 | doi = 10.1089/cbr.2008.0547 }}
*{{cite journal |vauthors=Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S, Shirakusa T |title=Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer |journal=Cancer Biother. Radiopharm. |volume=23 |issue=4 |pages=461–7 |date=August 2008 |pmid=18771350 |doi=10.1089/cbr.2008.0484 }}
* {{cite journal | vauthors = Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S, Shirakusa T | title = Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer | journal = Cancer Biotherapy & Radiopharmaceuticals | volume = 23 | issue = 4 | pages = 461–467 | date = August 2008 | pmid = 18771350 | doi = 10.1089/cbr.2008.0484 }}
*{{cite journal |vauthors=Sadahiro S, Mitomi T, Noto T, etal |title=[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=32 |issue=7 |pages=997–1005 |date=July 2005 |pmid=16044962 |url=http://www.pieronline.jp/openurl?issn=0385-0684&volume=32&issue=7&spage=997}}
* {{cite journal | vauthors = Sadahiro S, Mitomi T, Noto T, Kumada K, Hiki Y, Yamakawa T, Amano T, Oki S, Otani Y, Oka H, Takahashi T, Takemiya S, Nishiyama K, Yamamura T, Tsuchiya S, Ogawa N | title = [Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection] | language = Japanese | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 32 | issue = 7 | pages = 997–1005 | date = July 2005 | pmid = 16044962 | url = http://www.pieronline.jp/openurl?issn=0385-0684&volume=32&issue=7&spage=997 }}
*{{cite journal |vauthors=Shirao K, Hoff PM, Ohtsu A, etal |title=Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV |journal=J. Clin. Oncol. |volume=22 |issue=17 |pages=3466–74 |date=September 2004 |pmid=15277535 |doi=10.1200/JCO.2004.05.017 }}
* {{cite journal | vauthors = Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL | title = Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV | journal = Journal of Clinical Oncology | volume = 22 | issue = 17 | pages = 3466–3474 | date = September 2004 | pmid = 15277535 | doi = 10.1200/JCO.2004.05.017 }}
*{{cite journal |vauthors=Onoyama H, Urakawa T, Sugihara S, etal |title=[A noteworthy case of postoperative liver metastasis from gastric cancer which responded well to UFT therapy] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=27 |issue=11 |pages=1731–5 |date=October 2000 |pmid=11057325 }}
* {{cite journal | vauthors = Onoyama H, Urakawa T, Sugihara S, Hashimoto Y, Azumi Y, Takao S, Saitoh Y | title = [A noteworthy case of postoperative liver metastasis from gastric cancer which responded well to UFT therapy] | language = Japanese | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 27 | issue = 11 | pages = 1731–1735 | date = October 2000 | pmid = 11057325 }}
*{{cite journal |vauthors=Matsushita A, Hanazaki K, Noike T, etal |title=[Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=30 |issue=9 |pages=1327–32 |date=September 2003 |pmid=14518415 }}
* {{cite journal | vauthors = Matsushita A, Hanazaki K, Noike T, Nakagawa K, Misawa R, Nakata T, Nomura K, Kobayashi A, Miwa S, Miyagawa S, Kawasaki S | title = [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection] | language = Japanese | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 30 | issue = 9 | pages = 1327–1332 | date = September 2003 | pmid = 14518415 }}
*{{cite journal |vauthors=Ohashi Y, Watanabe M, Ikeda M, etal |title=[Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration—a case report] |language=Japanese |journal=Gan to Kagaku Ryoho |volume=35 |issue=13 |pages=2409–12 |date=December 2008 |pmid=19098413 |url=http://www.pieronline.jp/openurl?issn=0385-0684&volume=35&issue=13&spage=2409}}
* {{cite journal | vauthors = Ohashi Y, Watanabe M, Ikeda M, Nanami T, Yamazaki K, Yajima S, Oshima Y, Takeyama T, Ito M, Saito F | title = [Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration--a case report] | language = Japanese | journal = Gan to Kagaku Ryoho. Cancer & Chemotherapy | volume = 35 | issue = 13 | pages = 2409–2412 | date = December 2008 | pmid = 19098413 | url = http://www.pieronline.jp/openurl?issn=0385-0684&volume=35&issue=13&spage=2409 }}
*{{cite journal |vauthors=Nakagawa Y, Todoroki T, Morishita Y, etal |title=A long-term survivor after pancreaticoduodenectomy for metastatic undifferentiated carcinoma of an unknown primary |journal=Hepatogastroenterology |volume=55 |issue=86–87 |pages=1557–61 |year=2008 |pmid=19102342 }}
* {{cite journal | vauthors = Nakagawa Y, Todoroki T, Morishita Y, Mori K, Nakahaashi C, Ohkohchi N, Matsumoto H | title = A long-term survivor after pancreaticoduodenectomy for metastatic undifferentiated carcinoma of an unknown primary | journal = Hepato-Gastroenterology | volume = 55 | issue = 86-87 | pages = 1557–1561 | year = 2008 | pmid = 19102342 }}
*{{cite journal |vauthors=Ueda H, Tanaka H, Kida Y, Fukuchi H, Ichinose M |title=Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma |journal=Oncol. Rep. |volume=19 |issue=5 |pages=1355–61 |date=May 2008 |pmid=18425398 |url=http://www.spandidos-publications.com/or/19/5/1355 |doi=10.3892/or.19.5.1355|doi-access=free }}
* {{cite journal | vauthors = Ueda H, Tanaka H, Kida Y, Fukuchi H, Ichinose M | title = Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma | journal = Oncology Reports | volume = 19 | issue = 5 | pages = 1355–1361 | date = May 2008 | pmid = 18425398 | doi = 10.3892/or.19.5.1355 | doi-access = free }}
*{{cite journal |vauthors=Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH |title=Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer |journal=Cancer Chemother. Pharmacol. |volume=60 |issue=3 |pages=351–6 |date=August 2007 |pmid=17111120 |doi=10.1007/s00280-006-0377-4 |s2cid=29375226 }}
* {{cite journal | vauthors = Lin PC, Chen WS, Chao TC, Yang SH, Tiu CM, Liu JH | title = Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer | journal = Cancer Chemotherapy and Pharmacology | volume = 60 | issue = 3 | pages = 351–356 | date = August 2007 | pmid = 17111120 | doi = 10.1007/s00280-006-0377-4 | s2cid = 29375226 }}
*{{cite journal |vauthors=Ohwada S, Ikeya T, Yokomori T, etal |title=Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study |journal=Br. J. Cancer |volume=90 |issue=5 |pages=1003–10 |date=March 2004 |pmid=14997197 |pmc=2409633 |doi=10.1038/sj.bjc.6601619 }}
* {{cite journal | vauthors = Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y | title = Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study | journal = British Journal of Cancer | volume = 90 | issue = 5 | pages = 1003–1010 | date = March 2004 | pmid = 14997197 | pmc = 2409633 | doi = 10.1038/sj.bjc.6601619 }}
{{refend}}
{{refend}}


Revision as of 07:30, 20 June 2024

Tegafur/uracil
Structural formula of tegafur Structural formula of uracil
Combination of
TegafurAntineoplastic agent
UracilNucleobase
Clinical data
Trade namesUftoral, others
Identifiers
CAS Number
PubChem CID
DrugBank
UNII

Tegafur/uracil (abbreviation: UFT[1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer.

UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio.[1]

5-FU exhibits poor intestinal penetration[2][3] and significant intestinal[4][5] and hepatic first-pass metabolism[5] by DPD, resulting in low and erratic systemic bioavailibility as well as formation of toxic metabolites.[6] Tegafur, after being absorbed from the gastrointestinal tract and delivered to the liver by the portal venous system, is converted to the bioactive compound 5-FU by hepatic cytochrome P450 enzymes. The surfeit of uracil meanwhile competitively inhibits hepatic DPD, preventing immediate inactivation of the just formed 5-FU.[1]

Pharmacology

Uracil has also been stated to help protect the gastrointestinal tract from 5-FU toxicity and the related metabolites, with less side effects than 5-FU and other 5-FU related (pro)drugs.[citation needed]

Tetrahydrofuran metabolites of tegafur have been shown to exhibit antiangiogenic[7] effects and improve cytocidal performance of 5-FU, particularly in patients with over-expressed HIF-1.[citation needed]

Trial results

Trials using UFT for cancer treatment include pancreatic cancer, colorectal cancer,[8][9] liver cancer,[10] adenocarcinoma of the lung[11] and breast cancer[12][13] with significant gains over existing treatments, with reduced side effects, improved quality of life, improved disease free survival and/or overall survival.

History

The UFT combination was developed in Japan during the 1980s. UFT is approved in over 50 countries as a cancer therapy, most commonly for advanced colorectal cancer to replace 5FU, and has a low cost.[8] "[P]atients appeared strongly to prefer treatment with [oral] UFT/LV over [intravenous] 5-FU/LV."[14] In Japan, UFT is approved for cancer treatments including tumors of the colon/rectum, lung, breast, stomach, head and neck, liver, gallbladder, bile duct, pancreas, bladder, prostate, and cervix.[15] In the UK, tegafur/uracil with folinic acid is approved as first line treatment by the National Institute for Health and Clinical Excellence (NICE) for metastatic colorectal cancer.[16]

Manufacturing and marketing

Tegafur/uracil is marketed by companies including Merck Serono, Korea United and Jeil, Taiho, mostly in Asia, Europe, South America, Central America and South Africa.

It is made by various manufacturers and sold under a variety of names including: Tegafur-uracil, UFT, Ftorafur, Tefudex, Ufur and Uftoral. The UFT brand version is authorized for marketing in over 50 countries. Between 1984 and 2006, over 30 million patients were treated with UFT.[17]

References

  1. ^ a b c "Tegafur-uracil". NCI dictionaries. National Cancer Institute, U.S. Department of Health and Human Services. 2011-02-02. Retrieved 2024-06-20.
  2. ^ Ahmad N, Albassam AA, Faiyaz Khan M, Ullah Z, Mohammed Buheazah T, Salman AlHomoud H, et al. (May 2022). "A novel 5-Fluorocuracil multiple-nanoemulsion used for the enhancement of oral bioavailability in the treatment of colorectal cancer". Saudi Journal of Biological Sciences. 29 (5): 3704–3716. doi:10.1016/j.sjbs.2022.02.017. PMC 9280251. PMID 35844373.
  3. ^ Kumar A, Singh Arya PK, Jindal A (2024-03-05). "Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment". Journal of Dispersion Science and Technology: 1–13. doi:10.1080/01932691.2024.2325398. ISSN 0193-2691.
  4. ^ Gu J, Yuasa H, Hayashi Y, Watanabe J (August 1998). "First-pass metabolism of 5-fluorouracil in the perfused rat small intestine". Biological & Pharmaceutical Bulletin. 21 (8): 871–873. doi:10.1248/bpb.21.871. PMID 9743260.
  5. ^ a b Yuasa H, Gu J, Hayashi Y, Watanabe J (September 1998). "First-pass metabolism of 5-fluorouracil in rats". The Journal of Pharmacy and Pharmacology. 50 (9): 1019–1025. doi:10.1111/j.2042-7158.1998.tb06917.x. PMID 9811163.
  6. ^ Eisenmann ED, Talebi Z, Sparreboom A, Baker SD (January 2022). "Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions". Basic & Clinical Pharmacology & Toxicology. 130 Suppl 1 (Suppl 1): 23–35. doi:10.1111/bcpt.13623. PMC 8665934. PMID 34117715.
  7. ^ Watanabe T (October 2013). "Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer". Breast Cancer. 20 (4): 302–309. doi:10.1007/s12282-013-0451-9. PMC 3824200. PMID 23456736.
  8. ^ a b Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S (April 2006). "Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial". Japanese Journal of Clinical Oncology. 36 (4): 237–244. doi:10.1093/jjco/hyl014. PMID 16675478.
  9. ^ Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA (August 2008). "UFT (tegafur-uracil) in rectal cancer". Annals of Oncology. 19 (8): 1371–1378. doi:10.1093/annonc/mdn067. PMID 18381370.
  10. ^ Ishikawa T (May 2008). "Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma". World Journal of Gastroenterology. 14 (18): 2797–2801. doi:10.3748/wjg.14.2797. PMC 2710718. PMID 18473401.
  11. ^ Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. (April 2004). "A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung". The New England Journal of Medicine. 350 (17): 1713–1721. doi:10.1056/NEJMoa032792. PMID 15102997.
  12. ^ Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, et al. (March 2009). "Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial". Journal of Clinical Oncology. 27 (9): 1368–1374. doi:10.1200/JCO.2008.18.3939. PMID 19204202.
  13. ^ Nakayama T, Noguchi S (2010). "Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan". The Oncologist. 15 (1): 26–36. doi:10.1634/theoncologist.2009-0255. PMC 3227888. PMID 20080863.
  14. ^ "Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation". www.hta.ac.uk. Archived from the original on 18 November 2009. Retrieved 15 January 2022.
  15. ^ "Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer - Drugs.com MedNews". Drugs.com.
  16. ^ Capecitabine and tegafur uracil for metastatic colorectal cancer, Technical appraisal 61
  17. ^ Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer, June 2007, Merck's press-release

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tegafur/uracil&oldid=1230042525"